Inhaled Oxytocin and HPA Axis Reactivity

PHASE2CompletedINTERVENTIONAL
Enrollment

109

Participants

Timeline

Start Date

February 7, 2019

Primary Completion Date

July 25, 2023

Study Completion Date

July 25, 2023

Conditions
Depression, PostpartumAnxiety DisordersStress, Psychological
Interventions
DRUG

Intranasal Oxytocin

Six intranasal sprays of oxytocin. Each insufflation delivers 4 IUs of oxytocin for a total oxytocin dosage of 24 IUs.

DRUG

Placebo

Six intranasal sprays of placebo manufactured to mimic oxytocin nasal spray containing all equivalent ingredients except oxytocin.

Trial Locations (1)

27599

University of North Carolina School of Medicine, Chapel Hill

All Listed Sponsors
collaborator

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

NIH

lead

University of North Carolina, Chapel Hill

OTHER

NCT03593473 - Inhaled Oxytocin and HPA Axis Reactivity | Biotech Hunter | Biotech Hunter